Tumor inflammation-associated neurotoxicity

Last Updated: Thursday, August 13, 2026

Researchers discuss tumor inflammation-associated neurotoxicity (TIAN)—a toxicity syndrome distinct from cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome—that can emerge in patients treated with cell therapies for tumors in the central nervous system. In this review, they propose a toxicity grading scale for TIAN and discuss potential management.

Nature Medicine

Cancers

Prospects of chimeric antigen receptor T-Cell therapy in myelofibrosis: From immunopathogenesis to therapeutic strategies

Nature Medicine

Tumor inflammation-associated neurotoxicity

Transplantation and Cellular Therapy

Chimeric antigen receptor T-Cell therapy in autoimmune disorders: An expert panel opinion from the American Society for Transplantation and Cellular Therapy

Transplantation and Cellular Therapy

Long-Term follow-up of CD19 CAR-T for R/R B-NHL: Ki-67 as a prognostic factor for sustained remission

Critical Reviews in Oncology/Hematology

In vivo generation of CAR-T cells: Current obstacles, strategic solutions, and clinical translation

Cytotherapy

Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia

Bone Marrow Transplantation

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Exploratory Research in Clinical and Social Pharmacy

Transitions of care between pediatric onco-hematology and intensive care units: An exploratory study of healthcare professionals' perceptions and practices in medication management

Frontiers in Immunotherapy

Smart control of CAR-T cells: Emerging strategies for safer and more effective cancer immunotherapy

Molecular Therapy

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors

CAR T-Cell Therapy Resource Center

Tumor inflammation-associated neurotoxicity

Cancers

Prospects of chimeric antigen receptor T-Cell therapy in myelofibrosis: From immunopathogenesis to therapeutic strategies

Nature Medicine

Tumor inflammation-associated neurotoxicity

Transplantation and Cellular Therapy

Chimeric antigen receptor T-Cell therapy in autoimmune disorders: An expert panel opinion from the American Society for Transplantation and Cellular Therapy

Transplantation and Cellular Therapy

Long-Term follow-up of CD19 CAR-T for R/R B-NHL: Ki-67 as a prognostic factor for sustained remission

Critical Reviews in Oncology/Hematology

In vivo generation of CAR-T cells: Current obstacles, strategic solutions, and clinical translation

Cytotherapy

Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia

Bone Marrow Transplantation

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Exploratory Research in Clinical and Social Pharmacy

Transitions of care between pediatric onco-hematology and intensive care units: An exploratory study of healthcare professionals' perceptions and practices in medication management

Frontiers in Immunotherapy

Smart control of CAR-T cells: Emerging strategies for safer and more effective cancer immunotherapy

Molecular Therapy

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors

Identifying and Managing CAR T-Associated Hemophagocytic Lymphohistiocytosis Following Dual-Targeted CAR T-Cell Therapy

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Fast Facts #12: BCMA Targets